Eurand licenses cyclobenzaprine to Daewoong
This article was originally published in Scrip
Eurandhas licensed its once-daily formulation of the muscle relaxant cyclobenzaprine to Daewoong Pharmaceuticals for development and commercialisation in South Korea. The centrally acting product is used as an adjunct to rest for muscle spasms associated with acute musculoskeletal conditions, and uses Eurand's Diffucaps controlled-release technology. Cephalon markets the product in the US as Amrix.
You may also be interested in...
The alliance between China’s largest insurance group and Shionogi takes concrete shape as investment plans and new Asia companies move ahead, marking a major technology and geographic pivot for the Japanese pharma firm.
More progress for partners’ amyloid-targeting antibody portfolio as they look to demonstrate benefit of early intervention in pre-symptomatic disease in new collaborative Phase III trial.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.